| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P | 28% | $141,616,706 | 19,751,284 | BVF PARTNERS L P/IL | 06 Nov 2025 | |||
| Deep Track Capital, LP | 6.5% | $33,054,209 | 4,610,071 | Deep Track Capital, LP | 05 Nov 2025 | |||
| PRICE T ROWE ASSOCIATES INC /MD/ | 4.7% | -12% | $103,802,058 | -$12,891,083 | 2,974,271 | -11% | T. Rowe Price Associates, Inc. | 31 Mar 2025 |
| Avoro Capital Advisors LLC | 3.2% | -48% | $14,340,000 | -$15,415,500 | 2,000,000 | -52% | Avoro Capital Advisors LLC | 30 Sep 2025 |
| Chen Bihua | 3.1% | $108,084,177 | 1,994,173 | Chen Bihua | 30 Sep 2025 | |||
| FMR LLC | 1.1% | -88% | $5,212,098 | -$35,678,759 | 726,931 | -87% | FMR LLC | 30 Sep 2025 |
As of 30 Sep 2025, 132 institutional investors reported holding 37,454,837 shares of MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX). This represents 59% of the company’s total 63,492,063 outstanding shares.
The largest institutional shareholders of MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX) together control 54% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BVF INC/IL | 31% | 19,751,284 | 0% | 5.7% | $141,616,706 |
| Avoro Capital Advisors LLC | 3.2% | 2,000,000 | -52% | 0.19% | $14,340,000 |
| Cormorant Asset Management, LP | 3.1% | 1,994,173 | -77% | 0.99% | $14,298,220 |
| Balyasny Asset Management L.P. | 2.7% | 1,699,235 | +302% | 0.02% | $12,183,515 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.4% | 1,500,000 | 0.02% | $10,755,000 | |
| Schonfeld Strategic Advisors LLC | 1.5% | 965,405 | 0.05% | $6,921,951 | |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.3% | 822,957 | -69% | 0% | $5,901,000 |
| FMR LLC | 1.1% | 726,932 | -87% | 0% | $5,212,098 |
| Nuveen, LLC | 1% | 635,699 | -20% | 0% | $4,557,962 |
| TWO SIGMA INVESTMENTS, LP | 0.72% | 454,268 | 0.01% | $3,257,102 | |
| Ikarian Capital, LLC | 0.69% | 435,839 | 0.71% | $3,124,965 | |
| GOLDMAN SACHS GROUP INC | 0.57% | 362,871 | -72% | 0% | $2,601,785 |
| MARSHALL WACE, LLP | 0.51% | 321,109 | -39% | 0% | $2,302,353 |
| Verition Fund Management LLC | 0.43% | 272,768 | +1059% | 0.01% | $1,955,747 |
| First Turn Management, LLC | 0.41% | 262,643 | 0.28% | $1,883,150 | |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.41% | 258,779 | 0.05% | $1,855,445 | |
| MORGAN STANLEY | 0.4% | 256,655 | +494% | 0% | $1,840,218 |
| Boxer Capital Management, LLC | 0.39% | 250,000 | 0.57% | $1,792,500 | |
| Rhenman & Partners Asset Management AB | 0.33% | 207,000 | +360% | 0.16% | $1,484,190 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 0.31% | 195,490 | +908% | 0% | $1,220,835 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.31% | 194,741 | 0% | $1,396,293 | |
| Exome Asset Management LLC | 0.28% | 178,084 | 0.87% | $1,276,862 | |
| JPMORGAN CHASE & CO | 0.27% | 174,161 | +342% | 0% | $1,248,734 |
| ADAR1 Capital Management, LLC | 0.24% | 151,495 | +341% | 0.11% | $1,086,219 |
| HRT FINANCIAL LP | 0.23% | 143,275 | 0% | $1,027,000 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 92,984 | $1,225,045 | -$589 | $13.17 | 2 |
| 2025 Q3 | 37,454,837 | $268,355,894 | -$543,765,906 | $7.17 | 132 |
| 2025 Q2 | 58,588,386 | $2,765,378,029 | -$36,637,318 | $47.20 | 129 |
| 2025 Q1 | 59,722,970 | $2,333,396,034 | -$153,123,993 | $39.07 | 134 |
| 2024 Q4 | 63,244,825 | $3,424,722,018 | +$68,390,996 | $54.15 | 114 |
| 2024 Q3 | 62,105,859 | $3,131,140,770 | +$80,991,966 | $50.42 | 111 |
| 2024 Q2 | 60,658,898 | $2,667,135,853 | +$45,227,501 | $43.97 | 111 |
| 2024 Q1 | 59,346,206 | $2,980,957,803 | -$5,575,605 | $50.23 | 118 |
| 2023 Q4 | 73,060 | $4,412,093 | +$2,293,008 | $60.39 | 1 |
| 2023 Q3 | 56,323,727 | $3,210,449,994 | +$43,135,822 | $57.00 | 118 |
| 2023 Q2 | 56,057,516 | $2,858,934,047 | +$861,229,985 | $51.00 | 82 |
| 2023 Q1 | 39,419,149 | $843,176,754 | +$59,257,125 | $21.39 | 43 |
| 2022 Q4 | 37,748,780 | $396,358,589 | +$8,234,063 | $10.50 | 32 |
| 2022 Q3 | 36,855,847 | $291,356,995 | +$3,208,173 | $7.76 | 24 |
| 2022 Q2 | 36,396,348 | $189,719,000 | +$182,376,327 | $5.25 | 21 |
| 2022 Q1 | 653,872 | $7,258,000 | +$7,257,979 | $11.10 | 1 |